Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Slides:

Advertisements

Similar presentations

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

Advertisements

Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts Kenichi Suda 1 ;Kenji Tomizawa 2 ;Hiroshi.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.

EGFR Mutations in Lung Adenocarcinomas

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Enhanced DNA damage in IDH1 mutant glioma cells.

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Mutant EGFR complexes in lung cancer cell lines and immortalized human bronchial epithelial cells. Mutant EGFR complexes in lung cancer cell lines and.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

Volume 9, Issue 6, Pages (June 2006)

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

Pirh2 promotes p73 ubiquitination in vivo.

A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells Miguel A. Molina-Vila, PhD, Jordi Bertran-Alamillo,

Volume 9, Issue 6, Pages (June 2006)

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR Marie.

Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and.

Difference in Clonality as a Tool for Differential Diagnosis of Primary Versus Secondary Lung Neoplasms Giovanni Leuzzi, MD, Alfredo Cesario, MD, Maria.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Representative CT and PET/CT images of three patients with NSCLCs

EGFR Mutations in Lung Adenocarcinomas

Mark L. Kayton, MD, Mai He, MD, PhD, Maureen F. Zakowski, MD, Andre L

Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

Identification of the CD74–NRG1 fusion gene.

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

(A) yellow cDNA comparison among wild-type and ch mutants

A–c) Case 1, with epidermal growth factor receptor (EGFR) exon 21 mutations (V843I and L858R). a) Pedigree chart. a–c) Case 1, with epidermal growth factor.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.

Effects of knockdown of DDR1 levels on proliferation and apoptosis.

Peripheral CAF model. Peripheral CAF model. A, bright field (top) and fluorescence (bottom) micrographs of aggregates that contain RFP-tagged 344SQ cells.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

MAPJD expression in lung cancers.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

mRNA trafficking is regulated by the presence of a CPE

Representative CT and PET/CT images of three patients with NSCLCs

MPGES is expressed in epithelial cells in benign and malignant tumors of the colon. mPGES is expressed in epithelial cells in benign and malignant tumors.

FILM immunohistochemical protein signature is significantly associated with poor survival. FILM immunohistochemical protein signature is significantly.

Modeling of EGFR exon 20 insertions using the 3-dimensional structure of the EGFR kinase domain predicts different interactions with the erlotinib-binding.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

AMs contribute to the progression of EGFR-mutant lung adenocarcinoma.

Immunohistochemical analysis of dUTPase in human breast adenocarcinoma

Location of common clinically relevant mutations in EGFR

Inactivation of human TRAC and CD52 genes by TALENs

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Reduced klotho expression in pancreatic cancer.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

Prevalence of germline T790M.

Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

HPLC chromatograms using mobile phase containing CTAB and OSA showing complete separation of: A, phthaloylglutamine and phthaloylisoglutamine authentic.

Gastric, lung, and HPV-related cancer incidence and model fits.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

Expression of chemokine receptors in A-498 cell line.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Cells expressing mutant NADK-I90F exhibit low ROS and elevated NADP and NADPH levels. Cells expressing mutant NADK-I90F exhibit low ROS and elevated NADP.

Investigation of reactivity of D14 HLA-A

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas. Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas. A, estrogen receptor α (antibody estrogen receptor α-4) positive in the nucleus of malignant cells and sequencing chromatograms showing the presence of mutant form of EGFR (15-bp deletion in exon 19). Arrow, in-frame deletion mutation sequence. B, estrogen receptor β (antibody estrogen receptor β-1) positive in the nucleus of malignant cells and sequencing chromatograms showing the presence of mutant EGFR (L858R point mutation in exon 21). Arrow, CTG to CGG mutation. C, estrogen receptors α and β (same antibodies than as A and B) with negative expression in the malignant cells and sequencing chromatograms showing the presence of wild-type form of EGFR exon 19. Line, sequences 746 to 750. Maria G. Raso et al. Clin Cancer Res 2009;15:5359-5368 ©2009 by American Association for Cancer Research